AU2001289923A1 - Conjugates of defined stoichiometry - Google Patents

Conjugates of defined stoichiometry

Info

Publication number
AU2001289923A1
AU2001289923A1 AU2001289923A AU8992301A AU2001289923A1 AU 2001289923 A1 AU2001289923 A1 AU 2001289923A1 AU 2001289923 A AU2001289923 A AU 2001289923A AU 8992301 A AU8992301 A AU 8992301A AU 2001289923 A1 AU2001289923 A1 AU 2001289923A1
Authority
AU
Australia
Prior art keywords
conjugates
linker
polypeptide
defined stoichiometry
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289923A
Other languages
English (en)
Inventor
Herbert Andres
Frederic Donie
Rupert Herrmann
Hans-Peter Josel
Rudolf Vogel
Herbert Von Der Eltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10048417A external-priority patent/DE10048417A1/de
Priority claimed from EP01107491A external-priority patent/EP1245956A1/en
Application filed by Individual filed Critical Individual
Publication of AU2001289923A1 publication Critical patent/AU2001289923A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
AU2001289923A 2000-09-29 2001-09-26 Conjugates of defined stoichiometry Abandoned AU2001289923A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10048417.4 2000-09-29
DE10048417A DE10048417A1 (de) 2000-09-29 2000-09-29 Verbindungen mit verzweigtem Linker
EP01107491A EP1245956A1 (en) 2001-03-29 2001-03-29 Conjugates of defined stoichiometry
EP01107491.1 2001-03-29
PCT/EP2001/011101 WO2002027317A2 (en) 2000-09-29 2001-09-26 Conjugates of defined stoichiometry

Publications (1)

Publication Number Publication Date
AU2001289923A1 true AU2001289923A1 (en) 2002-04-08

Family

ID=26007222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289923A Abandoned AU2001289923A1 (en) 2000-09-29 2001-09-26 Conjugates of defined stoichiometry

Country Status (9)

Country Link
US (1) US7897404B2 (cg-RX-API-DMAC10.html)
EP (2) EP1364208B1 (cg-RX-API-DMAC10.html)
JP (1) JP3836429B2 (cg-RX-API-DMAC10.html)
AT (1) ATE313796T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001289923A1 (cg-RX-API-DMAC10.html)
CA (1) CA2420768C (cg-RX-API-DMAC10.html)
DE (1) DE60116146T2 (cg-RX-API-DMAC10.html)
ES (1) ES2254489T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002027317A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2012055815A1 (en) 2010-10-25 2012-05-03 Roche Diagnostics Gmbh Use of signal enhancing compounds in electrochemiluminescence detection
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
US20220331442A1 (en) * 2018-03-15 2022-10-20 Levim Biotech Llp Antibody-biomolecule conjugates linked through multifunctional macromolecule and uses thereof
AU2020348916B2 (en) * 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2493382A (en) * 1948-10-29 1950-01-03 American Cyanamid Co Automatic sample collector
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5047324A (en) * 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
US5804371A (en) 1994-07-25 1998-09-08 Boehringer Mannheim Gmbh Hapten-labelled peptides
DE59507438D1 (de) * 1994-07-25 2000-01-20 Roche Diagnostics Gmbh Hydrophile metallkomplexe
ES2148540T3 (es) * 1994-07-25 2000-10-16 Roche Diagnostics Gmbh Complejos metalicos con enlazador cargado.
WO1996003652A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
WO1996003651A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Metallchelat-markierte peptide
DE4430972A1 (de) * 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
GB9415143D0 (en) 1994-07-27 1994-09-14 Edwards Raymond Glycated haemoglobin assay
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications

Also Published As

Publication number Publication date
WO2002027317A3 (en) 2003-09-12
CA2420768A1 (en) 2002-04-04
EP1625857A3 (en) 2008-08-27
CA2420768C (en) 2012-09-25
ES2254489T3 (es) 2006-06-16
WO2002027317A2 (en) 2002-04-04
JP3836429B2 (ja) 2006-10-25
DE60116146T2 (de) 2006-09-14
US20040087501A1 (en) 2004-05-06
US7897404B2 (en) 2011-03-01
DE60116146D1 (de) 2006-01-26
EP1625857A2 (en) 2006-02-15
JP2004510162A (ja) 2004-04-02
EP1364208A2 (en) 2003-11-26
EP1364208B1 (en) 2005-12-21
ATE313796T1 (de) 2006-01-15

Similar Documents

Publication Publication Date Title
IL187389A0 (en) Nucleic acid molecule encoding a conjugate for treating activated immune cells
CA2223567A1 (en) Modified meningococcal polysaccharide conjugate vaccines
WO1998031393A3 (en) Polysaccharide-peptide-conjugates
NZ503007A (en) Conjugates that contain the homeodomain of antennapedia
CA2279270A1 (en) Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
HK1040406A1 (zh) 生物可分解聚酯與生物活性多肽之離子性分子共軛物
WO1999040112A8 (en) Neuroprotective peptides and uses thereof
WO1995027059A1 (en) Afamin: a human serum albumin-like protein
CA2423916A1 (en) Compounds with a branched linker
ATE313796T1 (de) Konjugate definierter stöchiometrie
WO1998019697A3 (en) Novel pharmaceutical compositions
WO2004096989A3 (en) Single chain antigen-binding polypeptides for polymer conjugation
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
WO2002091991A3 (en) Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
WO1998052590A3 (en) Improved delivery of disease modifiers
Greenfield et al. Toxin conjugates.
MY116630A (en) Bioactive and/or targeted dendrimer conjugates
CA2434514A1 (en) Dental floss holder
IT1311403B1 (it) Macchina a funzionamento continuo per l'imballaggio di gruppiorganizzati di prodotti in casse di cartone.